Autopsy report · NCT03891979

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

“Suspended due to Primary Investigator's decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

NYU Langone Health

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

Pembrolizumab; Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29

Participants

0

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.